ADVFN US – Market Content Editor
-

HSBC Expects Q3 Earnings and AI Demand to Support Global Equity Markets
HSBC expects third-quarter corporate earnings to provide further support for global equity markets, citing improving profit forecasts, growing demand for artificial intelligence computing capacity and signs of increased AI monetisation. In a research note published on Tuesday, Alastair Pinder, the bank’s head of emerging market and global equity strategy, maintained a positive outlook on equities…
-

Yardeni Research Cuts S&P 500 Year-End Target to 7,900 on Lower Valuation Expectations
Yardeni Research has reduced its year-end S&P 500 target to 7,900 from 8,400, citing expectations that continued risk aversion among investors will place further pressure on equity valuations. The investment research firm maintained its forecast for corporate earnings growth and continues to expect the US economy to avoid a recession through 2029. However, it lowered…
-

NYSE Short Interest Reaches Record High Above 21 Billion Shares, EPFR Reports
Short interest in stocks listed on the New York Stock Exchange (NYSE) reached a record high in late September, exceeding 21 billion shares for the first time, according to data from EPFR’s global market intelligence team. The firm’s semi-monthly figures showed that the number of shares held in short positions increased by 2.7% during the…
-

Fed Chair Warsh Sees AI Productivity Potential While Maintaining Focus on Inflation
Federal Reserve Chair Kevin Warsh said artificial intelligence could increase economic productivity over the medium term, although the transition may create uncertainty for employment, inflation and financial markets. Speaking at an International Monetary Fund forum during the annual meetings in Bangkok on Friday, Warsh said AI was initially contributing to economic demand, while its longer-term…
-

Bank of America Warns AI Investment Cycle Could Face Pressure From Competition and Falling Prices
Bank of America has identified similarities between the current artificial intelligence investment cycle and previous periods of large-scale capital spending, citing rising investment expectations, increased competition and declining prices for AI services. In a note to clients on Friday, investment strategist Sebastian Raedler examined whether AI infrastructure spending could follow the pattern of earlier capital…
-

World Bank Targets $19 Billion in Critical Minerals Financing Through 2030
The World Bank plans to increase its critical minerals business fivefold over the next five years, with a target of $19 billion in financing between fiscal 2026 and 2030, according to President Ajay Banga. Speaking during a plenary session at the International Monetary Fund and World Bank annual meetings in Bangkok, Banga said the development…
-

JPMorgan Expects Q3 Earnings Growth to Broaden Beyond AI Across US and European Equities
JPMorgan strategists expect third-quarter corporate earnings to provide support for equity markets, citing indications that profit growth is expanding beyond artificial intelligence-related companies and across a wider range of sectors. A team led by Mislav Matejka said earnings expectations remain elevated at the index level but become more moderate when the contribution from individual companies…
-

Tech Selloff Deepens as AI Financing Worries Drag Nasdaq Down and Oil Climbs Toward $100
Wall Street ended a difficult week on a sour note on Friday, as a renewed slide in technology stocks pushed the major indexes lower. The Nasdaq Composite took the brunt of the damage, while the Dow Jones Industrial Average held up far better thanks to strength in energy shares. Investors continued to worry about how…
-

Anavex Receives FDA IND Clearance for Blarcamesine in Fragile X Syndrome, Enabling Phase 2a Trial
Anavex Life Sciences gains regulatory clearance to begin U.S. clinical testing of blarcamesine for Fragile X syndrome, expanding its active development programs across three neurological indications. Key Investor Takeaways Why AVXL Stock Is in Focus Anavex Life Sciences (NASDAQ:AVXL) has secured FDA IND clearance for its investigational drug ANAVEX2-73, also known as blarcamesine, in Fragile…
-

Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans
Fractyl Health reports statistically significant reductions in weight regain following GLP-1 discontinuation, advancing its Revita treatment toward a potential FDA submission in late 2026. Key Investor Takeaways Why GUTS Stock Is in Focus Fractyl Health (NASDAQ:GUTS) has reported positive six-month results from its ongoing REMAIN-1 pivotal trial, meeting the first of two co-primary endpoints for…